PTC Therapeutics Inc (PTCT) Insider Trading
- $31,673,582.00
- $179,522,421.48
- April 6, 2026
- Mark Elliott Boulding
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 19, 2024 | CEO | 3,361 | $24.89 | Sell | $83,655.29 | |
| April 17, 2024 | CEO | 787 | $25.14 | Sell | $19,785.18 | |
| April 2, 2024 | EVP | 526 | $28.37 | Sell | $14,922.62 | |
| Jan. 30, 2024 | Insider | 618 | $27.25 | Sell | $16,840.50 | |
| Jan. 30, 2024 | VP | 794 | $27.25 | Sell | $21,636.50 | |
| Jan. 30, 2024 | CAO | 318 | $27.25 | Sell | $8,665.50 | |
| Jan. 22, 2024 | Director | 10,000 | $27.38 | Sell | $273,800.00 | |
| Jan. 8, 2024 | Director | 1,500 | $27.81 | Sell | $41,715.00 | |
| Jan. 8, 2024 | CEO | 2,237 | $28.64 | Sell | $64,067.68 | |
| Jan. 8, 2024 | VP | 1,457 | $28.64 | Sell | $41,728.48 | |
| Jan. 8, 2024 | CAO | 1,188 | $28.64 | Sell | $34,024.32 | |
| Jan. 8, 2024 | Insider | 1,569 | $28.64 | Sell | $44,936.16 | |
| Jan. 5, 2024 | CEO | 10,107 | $27.15 | Sell | $274,405.05 | |
| Dec. 12, 2023 | CFO | 7,700 | $25.81 | Buy | $198,737.00 | |
| Sept. 6, 2023 | Director | 11,666 | $39.86 | Sell | $465,006.76 | |
| May 11, 2023 | Director | 23,000 | $55.08 | Sell | $1,266,840.00 | |
| April 21, 2023 | Director | 4,328 | $55.05 | Sell | $238,256.40 | |
| April 21, 2023 | CAO | 4,692 | $55.06 | Sell | $258,341.52 | |
| April 18, 2023 | CEO | 1,211 | $52.04 | Sell | $63,020.44 | |
| April 18, 2023 | Insider | 732 | $52.04 | Sell | $38,093.28 | |
| April 17, 2023 | VP | 61,923 | $51.42 | Sell | $3,184,080.66 | |
| April 17, 2023 | Director | 11,429 | $51.03 | Sell | $583,221.87 | |
| March 31, 2023 | Director | 2,571 | $50.05 | Sell | $128,678.55 | |
| March 29, 2023 | CAO | 4,688 | $47.79 | Sell | $224,039.52 | |
| March 27, 2023 | CFO | 7,363 | $45.00 | Sell | $331,335.00 | |
| March 27, 2023 | Director | 10,000 | $45.10 | Sell | $451,000.00 | |
| March 27, 2023 | CAO | 26,658 | $45.09 | Sell | $1,202,009.22 | |
| Jan. 31, 2023 | VP | 812 | $45.63 | Sell | $37,051.56 | |
| Jan. 31, 2023 | Insider | 375 | $45.63 | Sell | $17,111.25 | |
| Jan. 31, 2023 | CFO | 575 | $45.63 | Sell | $26,237.25 | |
| Jan. 31, 2023 | CAO | 325 | $45.63 | Sell | $14,829.75 | |
| Jan. 31, 2023 | CEO | 2,320 | $45.63 | Sell | $105,861.60 | |
| Jan. 24, 2023 | CEO | 284 | $47.45 | Sell | $13,475.80 | |
| Jan. 24, 2023 | Insider | 359 | $47.45 | Sell | $17,034.55 | |
| Jan. 24, 2023 | CFO | 223 | $47.45 | Sell | $10,581.35 | |
| Jan. 11, 2023 | CEO | 1,189 | $44.36 | Sell | $52,744.04 | |
| Jan. 11, 2023 | CFO | 418 | $44.36 | Sell | $18,542.48 | |
| Jan. 11, 2023 | Insider | 383 | $44.36 | Sell | $16,989.88 | |
| Jan. 11, 2023 | COO | 2,244 | $44.36 | Sell | $99,543.84 | |
| Jan. 11, 2023 | VP | 495 | $44.36 | Sell | $21,958.20 | |
| Jan. 11, 2023 | CAO | 417 | $44.36 | Sell | $18,498.12 | |
| Jan. 9, 2023 | CEO | 1,786 | $41.66 | Sell | $74,404.76 | |
| Jan. 9, 2023 | COO | 731 | $41.66 | Sell | $30,453.46 | |
| Jan. 9, 2023 | VP | 835 | $41.66 | Sell | $34,786.10 | |
| Jan. 9, 2023 | CFO | 758 | $41.66 | Sell | $31,578.28 | |
| Jan. 9, 2023 | Insider | 716 | $41.66 | Sell | $29,828.56 | |
| Jan. 9, 2023 | CAO | 706 | $41.66 | Sell | $29,411.96 | |
| Oct. 18, 2022 | VP | 299 | $55.06 | Sell | $16,462.94 | |
| Sept. 20, 2022 | VP | 1,176 | $55.00 | Sell | $64,680.00 | |
| Aug. 9, 2022 | Director | 2,296 | $51.62 | Sell | $118,519.52 |
Insiders are both buying and selling PTC Therapeutics Inc stock.
The insider traders at PTC Therapeutics Inc are: Mark Elliott Boulding, Stuart Walter Peltz, Christine Marie Utter, Neil Gregory Almstead, Emily Luisa Hill, Eric Pauwels, Matthew B Klein, Allan Steven Jacobson, Mark Rothera, Lee Scott Golden, Stephanie Okey, David P Southwell, Claudia De Oliveira Ri Hirawat, Pierre Gravier, Marcio Souza, Dawn Svoronos, Emma Reeve, Hbm Healthcare Investments (Ca, Jerome B Zeldis, Michael Schmertzler, Shane William Charles Kovacs, Alethia Young, Matthew B. Klein, Adam Koppel, Richard Aldrich, Robert J Spiegel, Robert Spiegel, David Southwell, Michael Kranda, and Michael L Kranda
The most active insider trader at PTC Therapeutics Inc is Mark Elliott Boulding with 34 trades.
Stuart Walter Peltz has sold the most PTC Therapeutics Inc stock with a total value of $85,044,720.20.
Adam Koppel has bought the most PTC Therapeutics Inc stock with a total value of $37,500,000.00.
The most recent insider trade for PTC Therapeutics Inc was on April 6, 2026.
The single biggest insider buy for PTC Therapeutics Inc was from Adam Koppel with a total value of $18,750,000.00 on June 25, 2013.
The single biggest insider sell for PTC Therapeutics Inc was from Stuart Walter Peltz with a total value of $21,253,437.00 on Dec. 7, 2020.
